Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2008-01-30Clinical Trial Update: Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy [Phase 4]
Phase 4 trial update assessing the safety of Avonex (interferon beta-1a) in multiple sclerosis patients who have neutralizing antibodies to …
-
CLINICAL_TRIALS research · 2007-12-24Clinical Trial Update: A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
A completed serologic study assessing whether neutralizing antibody titers to interferon-beta correlate with biomarker responses in patients…
-
CLINICAL_TRIALS trial_result · 2007-12-17Clinical Trial Update: Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation [Phase 2]
A Phase 2 study in multiple sclerosis evaluated fatigue using three MRI assessments and transcranial magnetic stimulation. The trial is list…
-
CLINICAL_TRIALS research · 2007-09-21Clinical Trial Update: Correlation Between Cognitive Functions and MRI in Multiple Sclerosis
A clinical trial is examining the relationship between cognitive function and MRI findings in people with Multiple Sclerosis; sponsor is She…
-
CLINICAL_TRIALS trial_result · 2007-08-08Clinical Trial Update: Promoting Physical Activity for Persons With Multiple Sclerosis [NA]
This clinical trial update indicates a study aimed at promoting physical activity for people with Multiple Sclerosis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2007-07-18FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Betaseron (interferon beta-1b) from Bayer HealthCare Pharmaceuticals, typically involving labeli…
-
FDA approval · 2007-06-20FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental Biologics License Application for AVONEX (interferon beta-1a).
-
CLINICAL_TRIALS trial_result · 2007-05-14Clinical Trial Update: Optimizing IFN Beta - 1B Dose [Phase 3]
A Phase 3 trial evaluating optimized dosing of interferon beta-1B for multiple sclerosis has completed.
-
FDA approval · 2007-04-26FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Betaseron (interferon beta-1b) from Bayer HealthCare Pharmaceuticals Inc., resulting in an appro…
-
CLINICAL_TRIALS trial_result · 2007-04-04Clinical Trial Update: Cannabis for Spasticity in Multiple Sclerosis [Phase 1, Phase 2]
A clinical trial update indicates Phase 1/Phase 2 studies evaluating cannabis for spasticity in multiple sclerosis have been terminated.
-
FDA approval · 2007-03-22FDA Approved: TIZANIDINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for tizanidine from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2007-02-07FDA Approved: TIZANIDINE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for tizanidine submitted by Dr. Reddy's Laboratories Limited. The approval indicates regulatory clea…
-
FDA approval · 2007-02-02FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for Avonex (interferon beta-1a) submitted by Biogen Inc.
-
CLINICAL_TRIALS research · 2007-01-25Clinical Trial Update: Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis
A completed clinical trial update analyzing factors that influence patient adherence to disease-modifying therapy in multiple sclerosis.
-
CLINICAL_TRIALS research · 2007-01-24Clinical Trial Update: T-Cell Vaccination in Multiple Sclerosis (MS) [Phase 1, Phase 2]
Update on a T-cell vaccination approach being explored for multiple sclerosis in Phase 1 and Phase 2 trials.
-
FDA approval · 2006-11-09FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved Bayer's supplemental application for BETASERON (interferon beta-1b), updating the product's labeling.
-
FDA approval · 2006-10-20FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for BETASERON (interferon beta-1B) by Bayer HealthCare Pharmaceuticals Inc., resulting in changes to…
-
CLINICAL_TRIALS research · 2006-10-16Clinical Trial Update: Effects of Spinal Cord Injury on Female Sexual Response [NA]
A clinical trial update examining how spinal cord injury affects female sexual response, with related considerations for female sexual dysfu…
-
CLINICAL_TRIALS trial_result · 2006-09-14Clinical Trial Update: The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis [Phase 4]
Phase 4 trial update on escitalopram for depression in multiple sclerosis has been terminated, with no further efficacy or safety results re…
-
CLINICAL_TRIALS trial_result · 2006-08-29Clinical Trial Update: TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis [Phase 3]
Phase 3 clinical trial update for T-Cell Vaccination (TCV-01-002) in probable multiple sclerosis; the current status is unknown.
-
CLINICAL_TRIALS trial_result · 2006-08-18Clinical Trial Update: Yoga: Effect on Attention in Aging & Multiple Sclerosis [Phase 2]
This update notes the completion of a Phase 2 trial evaluating the effect of yoga on attention in individuals with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2006-08-18Clinical Trial Update: Natural Antioxidants in the Treatment of Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating natural antioxidants for the treatment of multiple sclerosis has completed.
-
FDA approval · 2006-07-28FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental NDA for ZANAFLEX (tizanidine hydrochloride) submitted by Covis Pharma US, Inc., resulting in updated labelin…
-
FDA approval · 2006-07-28FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental application for ZANAFLEX (tizanidine hydrochloride) submitted by Covis Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2006-07-07Clinical Trial Update: Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate [NA]
This clinical trial update reports an evaluation of gait in multiple sclerosis patients treated with glatiramer acetate.